Brokerages Set Humacyte, Inc. (NASDAQ:HUMA) Target Price at $11.71

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have received an average recommendation of "Buy" from the eight research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $11.71.

Several brokerages recently issued reports on HUMA. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price target on shares of Humacyte in a report on Tuesday, May 13th. Wall Street Zen upgraded shares of Humacyte from a "sell" rating to a "hold" rating in a research report on Thursday. Benchmark cut their target price on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Finally, HC Wainwright assumed coverage on shares of Humacyte in a research report on Wednesday, May 14th. They set a "buy" rating and a $4.00 target price on the stock.

Insider Buying and Selling

In other news, CFO Dale A. Sander purchased 20,000 shares of the company's stock in a transaction dated Thursday, April 10th. The shares were purchased at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the transaction, the chief financial officer now owns 40,600 shares of the company's stock, valued at approximately $62,118. This trade represents a 97.09% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Kathleen Sebelius purchased 50,000 shares of the company's stock in a transaction dated Tuesday, April 8th. The stock was purchased at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the transaction, the director now directly owns 91,207 shares in the company, valued at approximately $120,393.24. This trade represents a 121.34% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 83,993 shares of company stock worth $118,224 in the last ninety days. Company insiders own 5.10% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Humacyte by 10.8% in the 4th quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock worth $28,294,000 after purchasing an additional 543,995 shares during the period. Brookstone Capital Management acquired a new position in shares of Humacyte during the 4th quarter valued at $56,000. Wealth Effects LLC boosted its stake in Humacyte by 89.1% during the fourth quarter. Wealth Effects LLC now owns 121,400 shares of the company's stock worth $613,000 after acquiring an additional 57,200 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Humacyte in the fourth quarter worth $99,000. Finally, Swiss National Bank increased its stake in Humacyte by 5.8% in the fourth quarter. Swiss National Bank now owns 172,100 shares of the company's stock valued at $869,000 after purchasing an additional 9,400 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company's stock.

Humacyte Stock Performance

Shares of Humacyte stock traded up $0.13 during midday trading on Friday, hitting $2.53. 3,755,840 shares of the company traded hands, compared to its average volume of 3,765,812. The stock has a market cap of $392.45 million, a price-to-earnings ratio of -1.89 and a beta of 1.64. The firm's fifty day moving average price is $1.77 and its 200-day moving average price is $3.40. Humacyte has a 12 month low of $1.15 and a 12 month high of $9.97.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.09. The company had revenue of $0.52 million for the quarter, compared to the consensus estimate of $0.46 million. Equities research analysts forecast that Humacyte will post -1.27 earnings per share for the current year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.